An observational study in Atrial Fibrillation, sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases · Observational
The purpose of this study is to develop and implement quality improvement programs for the treatment of atrial fibrillation (AF) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of atrial fibrillation.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's enrollment of 67,028 is above the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Beijing Institute of Heart, Lung and Blood Vessel Diseases is the lead sponsor of 23 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospitalized patients of atrial fibrillation
Exclusion Criteria:
None
The overall composite of six performance measures for AF care
Performance measures for AF care including: 1. Proportion of patients received assessment of thromboembolic risk factors 2. Proportion of patients discharged on warfarin or other anticoagulant drug 3. Proportion of patients discharged on warfarin who have PT/INR follow-up planned prior to hospital discharge 4. Proportion of patients with left ventricular systolic dysfunction prescribed an ACEI or ARB at hospital discharge 5. Proportion of patients with left ventricular systolic dysfunction prescribed a beta blocker at hospital discharge 6. Proportion of patients with either coronary artery disease, cerebrovascular accident/transient ischemic attack, peripheral vascular disease or diabetes who were prescribed a statin at hospital discharge
Time frame: Duration of hospital stay, an expected average of 1 week
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Institute of Heart, Lung and Blood Vessel Diseases